CoChat
Sign Up
Cited by 75Neurotransmitter Receptor Influence on BehaviorNeuroscience and Neuropharmacology ResearchAttention Deficit Hyperactivity Disorder

Guanfacine’s mechanism of action in treating prefrontal cortical disorders: Successful translation across species

Open access
Arnsten, Amy F.T.·2020·Neurobiology of Learning and Memory
DOI 10.1016/j.nlm.2020.107327PMC PMC7567669
Open this paper in CoChat — free accountOpen PDF

Abstract

The selective norepinephrine (NE) α2A-adrenoceptor (α2A-AR) agonist, guanfacine (Intuniv™), is FDA-approved for treating Attention Deficit Hyperactivity Disorder (ADHD) based on research in animals, a translational success story. Guanfacine is also widely used off-label in additional mental disorders that involve impaired functioning of the prefrontal cortex (PFC), including stress-related disorders such as substance abuse, schizotypic cognitive deficits, and traumatic brain injury. The PFC subserves high order cognitive and executive functions including working memory, abstract reasoning, insight and judgment, and top-down control of attention, action and emotion. These abilities arise from PFC microcircuits with extensive recurrent excitation through NMDAR synapses. There is powerful modulation of these synapses, where cAMP-PKA opening of nearby potassium (K+) channels can rapidly and dynamically alter synaptic strength to coordinate arousal state with cognitive state, e.g. to take PFC “offline” during uncontrollable stress. A variety of evidence shows that guanfacine acts within the PFC via post-synaptic α2A-AR on dendritic spines to inhibit cAMP-PKA-K+ channel signaling, thus strengthening network connectivity, enhancing PFC neuronal firing, and improving PFC cognitive functions. Although guanfacine’s beneficial effects are present in rodent, they are especially evident in primates, where the PFC greatly expands and differentiates. In addition to therapeutic actions in PFC, stress-related disorders may also benefit from additional α2-AR actions, such as weakening plasticity in the amygdala, reducing NE release, and anti-inflammatory actions by deactivating microglia. Altogether, these NE α2-AR actions optimize top-down control by PFC networks, which may explain guanfacine’s benefits in a variety of mental disorders.

AI snapshot

Written from the paper’s full text.

TL;DR

This review argues that guanfacine improves prefrontal cortical function by stimulating postsynaptic α2A-adrenoceptors on layer III dlPFC spines, inhibiting cAMP-PKA-K+ signaling and strengthening network connectivity. It synthesizes cross-species evidence from rodents, monkeys, and humans supporting guanfacine’s use in ADHD and other PFC-related disorders, while noting that treatment may require preserved PFC substrate and early intervention.

Key findings

  • Guanfacine mimics norepinephrine at postsynaptic α2A-AR on dlPFC dendritic spines, inhibiting cAMP-PKA opening of HCN/KCNQ channels to strengthen recurrent excitation and enhance Delay cell firing; iontophoresis of guanfacine enhanced task-related firing, while yohimbine reduced it.
  • Systemic guanfacine improves PFC-dependent cognition across species: it improves working memory in wild-type mice but not α2A-AR mutant mice, in aged rats and monkeys, and produces small but significant enhancing effects on working memory, paired associates learning, and planning in healthy humans.
  • Daily guanfacine prevented chronic stress-induced loss of mPFC dendritic spines and preserved working memory in rats, and protected against hypoxia-induced spine, neuron, and working memory loss; α2A-AR on activated microglia may also reduce inflammation and phagocytosis of spines.
  • Guanfacine was FDA approved for ADHD in 2009 under the brand name Intuniv, and is used off-label or experimentally in oppositional defiant/conduct disorders, autism spectrum disorders, trauma/abuse, TBI, stroke, infection, substance abuse, and schizophrenia-spectrum disorders; a trial in elderly humans >75 years did not show significant improvement.

Methods

  • Design: narrative review of basic neuroscience and clinical literature on guanfacine’s mechanism of action in prefrontal cortex, spanning rodent, monkey, and human studies.
  • Data/sample: no new primary data; the paper synthesizes cited animal experiments, human trials, imaging studies, and clinical reports, including genetic, pharmacological, electrophysiological, ultrastructural, and behavioral evidence.
  • Main analysis: qualitative, mechanistic synthesis organized around PFC microcircuits, α2A-AR signaling, stress protection, cross-species cognitive effects, and clinical disorders treated with guanfacine.

Limitations

  • The paper states that some substrate for guanfacine’s beneficial actions must remain—α2A-AR-expressing PFC dendritic spines—so treatment early in the disorder may be essential; it also notes that improving cognition in healthy subjects is challenging, possibly due to ceiling effects on neuronal firing.
  • The paper states that off-label use in additional PFC disorders is widespread but often has only limited empirical demonstrations of efficacy, with little corporate interest in funding large trials now that Intuniv is generic; it also reports negative or mixed results, including no significant improvement in a low-dose trial in elderly humans >75 years, no efficacy in a placebo-controlled trial of veterans with longstanding PTSD, and mixed results for cannabis withdrawal.
  • Evident from the text: this is a narrative review without a systematic search strategy or quantitative meta-analysis, and many mechanistic conclusions rely heavily on animal and in vitro studies, with the paper itself noting profound rodent-primate differences and recommending primates for translational cognitive research whenever possible.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1016/j.nlm.2020.107327

Cites

180 of 180 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Claims the paper makes

83 of 155 cited sources checked · 41 supported · 3 flagged · accuracy not yet measured

  • Interpretationcitation

    The increased BDNF and decreased caspase 3 may be induced by calcium overload of mitochondria with high levels of cAMP-calcium signaling.

    “which may be induced by calcium overload of mitochondria with high levels of cAMP-calcium signaling”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites Lencesova & Krizanova, 2012 source

      The figure caption in the Conclusion (page unavailable) says that calcium transferred to mitochondria leads to activation of caspase 3, contrary to the claimed decrease. The “IP 3 receptors and apoptosis” section likewise links mitochondrial calcium accumulation to cell-death signaling. The passages found do not link this mechanism to increased BDNF or high cAMP-calcium signaling. (LLM, conf=0.84)

      Checked by a reasoning model — may be wrong.

      Experimental — accuracy not yet measured
  • Premisecitation

    Object reversal task depends on more ventral PFC circuits.

    “a task that Elizabeth Murray’s lab at NIMH has shown depends on more ventral PFC circuits”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites Rudebeck, Saunders, Lundgren, & Murray, 2017 source

      The Discussion (VLPFC) reports that monkeys with VLPFC lesions were not impaired even when object–outcome associations were reversed. It concludes that neither OFC nor VLPFC is required for object discrimination reversal learning in macaques, contrary to the claim that the task depends on these ventral PFC areas. (LLM, conf=0.88)

      Checked by a reasoning model — may be wrong.

      Experimental — accuracy not yet measured
  • Premisecitation

    The beneficial effects of α2-AR agonists for higher cognitive function were first discovered in aged monkeys.

    “The beneficial effects of α2-AR agonists for higher cognitive function were first discovered in aged monkeys (Arnsten et al., 1988, Arnsten and Goldman-Rakic, 1985)”
    Quote in the paperNot a substantial claim1 of 2 sources checked
    • cites Arnsten et al., 1988 source
    • cites Arnsten and Goldman-Rakic, 1985 source
  • Premisecitation

    ADHD is associated with slowed or impaired development of the right lateral PFC.

    “ADHD is associated with slowed (Shaw et al., 2007) or impaired (Shaw et al., 2009) development of the right lateral PFC, the PFC region needed for inhibiting inappropriate actions and attention to distractors (Aron, Robbins, & Poldrack, 2004).”
    Quote in the paperNot a substantial claim2 of 2 sources checked
    • cites Shaw et al., 2007 source

      The Discussion (page unavailable in our copy) says cortical maturation delay in ADHD was most prominent in the lateral prefrontal cortex, supporting the 'slowed' development attributed to Shaw et al. (2007). It does not specify the right lateral PFC, so the right-sided localization is not established by the passages found. The sentence attributes 'impaired' development to a different citation. (LLM, conf=0.82)

      Experimental — accuracy not yet measured
    • cites Shaw et al., 2009 source
  • Premisecitation

    Beneficial effects of α2-AR agonists on cognition arise from postsynaptic α2A-AR in PFC.

    “early research determined that the beneficial effects of α2-AR agonists on cognition arose from postsynaptic receptor actions in the PFC (Arnsten and Goldman-Rakic, 1985, Cai et al., 1993), with a pharmacological profile consistent with the α2A-AR subtype (Arnsten et al., 1988, Arnsten and Leslie, 1991), a finding later confirmed in genetically altered mice (Franowicz et al., 2002).”
    Quote in the paperSubstantial claim1 of 3 sources checked
    • cites Arnsten and Goldman-Rakic, 1985 source
    • cites Cai et al., 1993 source
    • cites Franowicz et al., 2002 source
  • May combine two claims. 34
  • Classified as probably not a substantial claim. 9

  • May combine two claims.

    Premisecitation

    A case report suggests guanfacine may be especially helpful in young adults with schizophrenia and a childhood history of abuse, and can improve insight.

    “a case report by Bardoloi (2020) suggests that guanfacine may be especially helpful in young adults with schizophrenia and a childhood history of abuse, and that it can improve insight”
    Quote in the paperNot a substantial claim2 of 2 sources checked
    • cites Bardoloi (2020) source

      The Clinical history says the patient had no history of emotional or physical abuse, contrary to the claimed childhood-abuse history. The Conclusion does report improved insight after guanfacine was added, but this case cannot support the claim about young adults with schizophrenia and a history of abuse. (LLM, conf=0.88)

      Checked by a reasoning model — may be wrong.

      Experimental — accuracy not yet measured
    • cites Bardoloi, 2018 source

      In “Improving Executive Function to Improve Insight in Acutely Ill Psychiatric Patients” (page unavailable), the paper proposes guanfacine as a possible way to improve insight. It does not report a case or say guanfacine is especially helpful for young adults with schizophrenia and a childhood history of abuse; its discussion of insight improvement is hypothetical. (LLM, conf=0.88)

      Experimental — accuracy not yet measured
    • Rests on an assumption: Many atypical antipsychotics have α2A-AR-blocking properties.

  • May combine two claims.

    Premisecitation

    Schizophrenia is associated with accelerated gray matter loss in PFC, including loss of dendrites and spines in dlPFC.

    “Schizophrenia is associated with accelerated gray matter loss in PFC (Cannon, Chung, He, Sun, Jacobson, van Erp, & Consortium, 2014), including loss of dendrites and spines in the dlPFC (Glantz & Lewis, 2000).”
    Quote in the paperNot a substantial claim1 of 2 sources checked
    • cites Cannon et al., 2014 source

      The Discussion reports faster gray matter loss in prefrontal regions among clinical high-risk individuals who developed psychosis than among non-converters and healthy controls. That supports accelerated prefrontal loss around psychosis onset, but the study does not establish it for schizophrenia generally. The separate claim about dendrites and spines is attributed to Glantz and Lewis, not to this source. (LLM, conf=0.84)

      Experimental — accuracy not yet measured
    • cites Glantz & Lewis, 2000 source

  • May combine two claims.

    Premisecitation

    Stress exposure weakens PFC function, and severe stressors that cause PTSD can cause atrophy of PFC.

    “As described below, stress exposure weakens PFC function, and severe stressors that cause PTSD can cause atrophy of PFC (Kühn and Gallinat, 2013, Meng et al., 2016).”
    Quote in the paperNot a substantial claim1 of 2 sources checked
    • cites Kühn and Gallinat, 2013 source
    • cites Meng et al., 2016 source

      The Discussion section on single-incident traumas says stress can impair medial PFC function, and the Results report reduced medial PFC grey matter in patients with PTSD after single-incident trauma compared with trauma-exposed controls (page numbers unavailable). These findings support the functional and structural parts of the claim, but the meta-analysis does not establish that severe stressors cause PFC atrophy. (LLM, conf=0.83)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    Daily guanfacine administration prevented spine loss and working memory deficits.

    “and daily guanfacine administration prevented spine loss and working memory deficits (Hains et al., 2015), which may help to explain its utility in treating stress-related disorders.”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites Hains et al., 2015 source

      The Discussion (Summary and evaluation of data) says daily guanfacine protected spine density and working-memory performance in rats exposed to repeated restraint stress. It also says cognitive performance did not completely normalize, so describing working-memory deficits as prevented overstates the result. (LLM, conf=0.86)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    Guanfacine was the most potent α2A-AR-selective agonist with the least side effects.

    “Research with visiting Chinese scientist, Jing-Xia Cai, showed that the α2A-AR-selective agonist, guanfacine, was the most potent agent with the least side effects, suggesting that the beneficial effects arose from what is now called the α2A-AR subtype (Arnsten et al., 1988).”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites Arnsten et al., 1988 source

      The Summary reports that guanfacine was the most potent of the three agents for improving delayed-response performance in aged monkeys and the least potent at producing sedation or hypotension. The Discussion links its benefit to selectivity for a proposed receptor subtype called Ri, but our copy does not identify Ri as what is now called α2A-AR; that specific identification is not supported by this source. (LLM, conf=0.86)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    In dlPFC working memory circuits, cAMP-PKA signaling opens nearby K+ channels to rapidly weaken synaptic strength and reduce Delay cell firing.

    “In these circuits, cAMP-PKA signaling opens nearby potassium (K+) channels to rapidly weaken synaptic strength and reduce Delay cell firing (Fig. 3C; (Arnsten et al., 2012)).”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites Arnsten et al., 2012 source

  • May combine two claims.

    Premisecitation

    α2A-AR stimulation deactivates microglia and has anti-inflammatory actions.

    “α2A-AR stimulation deactivates microglia and thus has anti-inflammatory actions.”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites Gyoneva & Traynelis, 2013 source

      The Results (page unavailable) show that an α2-selective agonist reduced process ramification in LPS-activated microglia, consistent with α2A receptor involvement. The paper studies motility; it does not show that α2A stimulation deactivates microglia or produces an anti-inflammatory effect. (LLM, conf=0.85)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    Emerging data indicate primate-unique cell types and profound differences in transcriptomic signatures between rodents and primates.

    “Emerging data also indicate primate-unique cell types, and profound differences in transcriptomic signatures between rodents and primates (Krienen et al., 2019).”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites Krienen et al., 2019 source

  • May combine two claims.

    Premisecitation

    With chronic stress exposure, there is architectural loss of mPFC spines and dendrites that correlates with impaired PFC cognitive functioning.

    “With chronic stress exposure, there is architectural loss of mPFC spines and dendrites (Moda-Sava et al., 2019, Radley et al., 2006) that correlates with impaired PFC cognitive functioning (Hains et al., 2009, Hains et al., 2015, Liston et al., 2006).”
    Quote in the paperSubstantial claim2 of 2 sources checked
    • cites Moda-Sava et al., 2019 source
    • cites Hains et al., 2009 source

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    Aging causes weakening and removal of dlPFC synapses on spines.

    “Finally, aging causes weakening and removal of dlPFC synapses on spines (Morrison & Baxter, 2012), a process which is worsened by Alzheimer’s Disease (AD), where tau pathology often begins in the medial and ventral areas and moves to dlPFC as the disease progresses, correlating with the rise in dementia (Bussière et al., 2003).”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites Morrison & Baxter, 2012 source

      The ‘Synaptic Aging in the Prefrontal Cortex’ section reports age-related loss of axospinous synapses in rhesus monkey dlPFC, particularly those on thin spines. It does not establish that the remaining spine synapses weaken; reduced plasticity associated with spine loss is not the same finding. (LLM, conf=0.84)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    Anti-inflammatory effects of α2A-AR agonists contribute to their widespread use as co-anesthetics in surgery, where they reduce incidence of emergence delirium.

    “contribute to their widespread use as co-anesthetics in surgery, where they reduce the incidence of emergence delirium”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites Zhang et al., 2020 source

      The Results (Incidence of POD and NRS Scores; page unavailable) report less postoperative delirium with intraoperative dexmedetomidine, and the Discussion reports lower IL-6 and TNF-α levels. But the paper studies postoperative delirium in elderly hip-fracture patients, not emergence delirium, and does not establish that anti-inflammatory effects drive widespread use of α2A-AR agonists as co-anesthetics. The cited paper is marked retracted. (LLM, conf=0.87)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    Fox et al. showed guanfacine could improve PFC functions (inhibitory control, Stroop interference) and reduce drug cravings in cocaine addicts.

    “Fox et al. showed that guanfacine could improve PFC functions (inhibitory control, Stroop interference) and reduce drug cravings in cocaine addicts (Fox et al., 2015, Fox et al., 2012).”
    Quote in the paperSubstantial claim2 of 2 sources checked
    • cites Fox et al., 2015 source

      The Abstract Results report improved inhibitory control in early-abstinent cocaine-dependent participants. But the Results > Cognitive measures section says Stroop performance improved in both the guanfacine and placebo groups, with no guanfacine-specific effect. This paper does not report a craving reduction from its own trial; its Discussion mentions craving decreases in connection with a separate 2014 study. (LLM, conf=0.90)

      Experimental — accuracy not yet measured
    • cites Fox et al., 2012 source

      The Abstract reports reduced cue-induced cocaine craving and increased prefrontal activity with guanfacine in cocaine-dependent participants. The Discussion says improved executive function was not directly assessed in this study, and the Introduction discusses Stroop-task findings as background, not as an effect of guanfacine measured here. Thus the claim overstates the evidence for improved inhibitory control and Stroop interference. (LLM, conf=0.90)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    McKee et al. (2015) found guanfacine reduced stress-induced smoking in the lab and helped people quit smoking at home.

    “McKee et al. (2015) found that guanfacine reduced stress-induced smoking in the lab, and helped people quit smoking at home.”
    Quote in the paperSubstantial claim1 of 1 sources checked
    • cites McKee et al. (2015) source

      The Discussion (page not supplied) reports that guanfacine reduced stress-precipitated smoking lapse in the laboratory and reduced cigarette use during a brief treatment period. It also says that an effect on complete abstinence was not demonstrated, so the claim that it helped people quit smoking at home overstates the finding. (LLM, conf=0.90)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    Guanfacine is approved for treating ADHD in USA, Canada, Europe and Japan, the latter in adults as well as children.

    “Guanfacine is currently approved for treating ADHD in the USA, Canada, Europe and iJapan, the latter in adults (Iwanami, Saito, Fujiwara, Okutsu, & Ichikawa, 2020) as well as children.”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites Iwanami, Saito, Fujiwara, Okutsu, & Ichikawa, 2020 source

  • May combine two claims.

    Premisecitation

    An open label study found guanfacine reduced symptoms of re-experiencing trauma, avoidance of others, and hyperarousal.

    “An open label study found that guanfacine reduced symptoms of re-experiencing the trauma, avoidance of others, and hyperarousal”
    Quote in the paperNot a substantial claim1 of 2 sources checked
    • cites Arnsten et al., 2015 source
    • cites Connor et al., 2013 source

  • May combine two claims.

    Premisecitation

    Guanfacine is often used as adjunct to stimulant medication, as the combination optimizes therapeutic actions while diminishing side effects.

    “Guanfacine is often used as adjunct to stimulant medication, as the combination optimizes the therapeutic actions while diminishing side effects (McCracken et al., 2016).”
    Quote in the paperNot a substantial claim1 of 1 sources checked
    • cites McCracken et al., 2016 source

      The Discussion (page unavailable) reports modest additional ADHD symptom benefits from combining guanfacine with a stimulant, without an increased overall side-effect burden. It does not establish that the combination diminishes side effects: sedation, fatigue, and somnolence were more frequent in the guanfacine groups. The cited trial also does not establish how often guanfacine is used as an adjunct. (LLM, conf=0.90)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    Studies of humans with TBI support the view that guanfacine improves working memory and enhances fMRI BOLD activation of PFC.

    “Studies of humans with TBI support this view (McAllister et al., 2004, McAllister et al., 2011), including evidence of improved working memory and enhanced fMRI BOLD activation of PFC (McAllister et al., 2011).”
    Quote in the paperSubstantial claim1 of 2 sources checked
    • cites McAllister et al., 2004 source
    • cites McAllister et al., 2011 source

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Premisecitation

    A subset of COVID-19 patients report sustained mental problems.

    “where a subset of patients report sustained mental problems (Heneka et al., 2020, Pinna et al., 2020)”
    Quote in the paperNot a substantial claim2 of 2 sources checked
    • cites Heneka et al., 2020 source

      The Main text reports evidence of cognitive impairment in one third of patients at discharge, supporting the claim that a subset had cognitive problems. But it describes long-term consequences as a risk requiring prospective study, not as sustained mental problems that patients had reported. No page numbers are provided in our copy. (LLM, conf=0.86)

      Experimental — accuracy not yet measured
    • cites Pinna et al., 2020 source

      The Results report cognitive abnormalities, particularly short-term memory impairment, in 12 of 50 COVID-19 patients. But the Limitations state that long-term follow-up data were unavailable, so the paper does not establish that these problems were sustained. (LLM, conf=0.88)

      Experimental — accuracy not yet measured

  • Probably not a substantial claim: may not pass S3 (load-bearing).

    Interpretationcitation

    Anti-inflammatory effects of guanfacine may be useful for treating long-term neural consequences of COVID-19.

    “The anti-inflammatory effects of guanfacine may also be useful for treating the long-term neural consequences of COVID-19”
    Quote in the paperNot a substantial claim2 of 2 sources checked
    • cites Heneka et al., 2020 source

      The Main text (page unavailable) links systemic inflammation in COVID-19 to possible long-term cognitive decline and neurodegeneration. It does not mention guanfacine, establish its anti-inflammatory effects, or suggest that it could treat those consequences. (LLM, conf=0.83)

      Experimental — accuracy not yet measured
    • cites Pinna et al., 2020 source

      The Discussion (page unavailable) describes neurological manifestations of COVID-19, but does not discuss guanfacine or its anti-inflammatory effects. The Limitations (page unavailable) state that long-term follow-up data were unavailable. Searches for guanfacine and treatment of long-term neurological consequences found no supporting passage in our copy. (LLM, conf=0.75)

      Experimental — accuracy not yet measured

  • May combine two claims.

    Premisecitation

    Guanfacine protects mPFC dendritic spines, neurons and working memory performance from physiological stress of hypoxia.

    “Guanfacine also protects mPFC dendritic spines, neurons and working memory performance from the physiological stress of hypoxia”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites Kauser et al., 2013 source

  • Classified as probably not a substantial claim.

    Premisecitation

    Persistent firing across delay period arises from pyramidal cells with shared preferred directions exciting each other through glutamatergic synapses on spines.

    “She posited that the persistent firing across the delay period arose from pyramidal cells with shared “preferred directions”, exciting each other through glutamatergic synapses on spines (Fig. 2C-D).”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Premisecitation

    Infusion of α2-AR antagonist yohimbine into monkey dlPFC impaired working memory, impulse control and locomotor activity, producing an 'ADHD-like' phenotype.

    “Conversely, infusion of the α2-AR antagonist, yohimbine, into the monkey dlPFC impaired working memory (Li & Mei, 1994), impulse control (Ma, Qi, Peng, & Li, 2003) and regulation of locomotor activity (Ma, Arnsten, & Li, 2005), producing an “ADHD-like” phenotype.”
    Quote in the paperSubstantial claim0 of 3 sources checked
    • cites Li & Mei, 1994 source
    • cites Ma et al., 2003

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

    • cites Ma et al., 2005

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

  • May combine two claims.

    Interpretationreasoning

    Guanfacine's engagement of α2A-AR in PFC may have coordinated actions, both strengthening connections on spines and reducing local phagocytic actions by glia.

    “Thus, guanfacine’s engagement of α2A-AR in PFC may have coordinated actions, both strengthening connections on spines and reducing local phagocytic actions by glia.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Interpretationreasoning

    A variety of evidence indicates that guanfacine improves PFC function by mimicking NE's beneficial actions at post-synaptic α2A-AR on dlPFC spines, strengthening PFC network connectivity via inhibition of cAMP-PKA-K+ signaling.

    “A variety of evidence indicates that guanfacine improves PFC function by mimicking NE’s beneficial actions at post-synaptic α2A-AR on dlPFC spines, strengthening PFC network connectivity via inhibition of cAMP-PKA-K+ signaling (Fig. 5 A).”
    Quote in the paperSubstantial claim
    • Rests on an assumption: The mechanisms of guanfacine action in PFC discovered in animals (monkeys, rodents) are the same in humans.

  • Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based).

    Interpretationreasoning

    These factors may help explain why guanfacine is particularly helpful in treating women with stress-related disorders such as substance abuse.

    “As discussed below, these factors may help to explain why guanfacine is particularly helpful in treating women with stress-related disorders such as substance abuse.”
    Quote in the paperNot a substantial claim
    • Rests on an assumption: The mechanisms of guanfacine action in PFC discovered in animals (monkeys, rodents) are the same in humans.

  • May combine two claims.

    Premisecitation

    Either systemic or direct infusion of guanfacine into ventral PFC improves performance of monkeys performing paired associates learning task.

    “Either systemic or direct infusion of guanfacine into the ventral PFC improved the performance of monkeys performing a paired associates learning task”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites Wang et al., 2004 source

  • May combine two claims.

    Premisecitation

    Development of guanfacine's use in ADHD was based on understanding its prefrontal enhancement in monkeys and recognition that ADHD is a PFC disorder.

    “with the development of guanfacine’s use in ADHD based on understanding its prefrontal enhancement in monkeys (Arnsten and Contant, 1992, Arnsten et al., 1996), and the recognition that ADHD is a PFC disorder.”
    Quote in the paperSubstantial claim0 of 2 sources checked
    • cites Arnsten and Contant, 1992 source
    • cites Arnsten et al., 1996 source

  • May combine two claims.

    Interpretationcitation

    It can be challenging to improve cognition in healthy subjects, possibly related to ceiling effects on neuronal firing.

    “However, it can be challenging to improve cognition in healthy subjects (Muller et al., 2005), possibly related to ceiling effects on neuronal firing”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites Muller et al., 2005 source

  • May combine two claims.

    Premisecitation

    Guanfacine can reduce stress-induced PFC dysfunction and decrease substance abuse in subjects with nicotine or cocaine addiction.

    “have shown that guanfacine can reduce stress-induced PFC dysfunction and decrease substance abuse in subjects struggling with addictions to nicotine or cocaine.”
    Quote in the paperSubstantial claim

  • Probably not a substantial claim: may not pass S3 (load-bearing), S4 (based). May combine two claims.

    Premisereasoning

    Off-label use of guanfacine in additional PFC disorders is widespread, but often with only limited empirical demonstrations of efficacy.

    ““Off label” use of guanfacine in additional PFC disorders is widespread, but often with only limited empirical demonstrations of efficacy”
    Quote in the paperNot a substantial claim
    • Rests on an assumption: Many disorders helped by guanfacine have psychological or physiological stress as an etiological factor.

  • May combine two claims.

    Premisecitation

    Guanfacine relieves cardinal symptoms of ADHD in children and adolescents, including improved impulse control and better regulation of attention, in early small trials and later large Phase III studies.

    “Guanfacine has been shown to relieve cardinal symptoms of ADHD in children and adolescents, including improved impulse control and better regulation of attention, in early, small trials (Hunt et al., 1995, Scahill et al., 2001), and later in multiple, large Phase III studies”
    Quote in the paperSubstantial claim0 of 3 sources checked
    • cites Hunt et al., 1995 source
    • cites Scahill et al., 2001 source
    • cites Biederman et al., 2008 source

  • May combine two claims.

    Premisecitation

    TBI to posterior cortex in rats reduces PFC spine density and impairs working memory.

    “as well as reducing PFC spine density and impairing working memory (Zhao et al., 2018)”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites Zhao et al., 2018 source

  • Probably not a substantial claim: may not pass S4 (based).

    Premisenone given

    A wide variety of disorders involving PFC dysfunction are currently being treated with guanfacine or tested in experimental studies.

    “A wide variety of disorders that involve PFC dysfunction are currently being treated with guanfacine, or tested in experimental studies”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Interpretationcitation

    A large number of studies indicate guanfacine may be efficacious in treating substance abuse disorders by strengthening PFC top-down control to resist cravings and impulsive consumption, and reducing stress responses that underlie drug intake.

    “A large number of studies indicate that guanfacine may be efficacious in treating substance abuse disorders, by strengthening PFC top-down control to resist cravings and impulsive consumption, and reducing the stress responses that often underlie drug intake.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Interpretationreasoning

    Guanfacine treatment may be helpful to normalize intracellular signaling and promote synaptic strength after TBI.

    “Thus, guanfacine treatment may be helpful to normalize intracellular signaling and promote synaptic strength.”
    Quote in the paperSubstantial claim

  • May combine two claims.

    Premisecitation

    Guanfacine is used to treat patients with co-morbid ADHD and Tourette's syndrome, where stimulant medication can aggravate tics.

    “It is also used to treat patients with co-morbid ADHD and Tourette’s syndrome, where stimulant medication can aggravate the appearance of tics (Scahill et al., 2001).”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites Scahill et al., 2001 source

  • May combine two claims.

    Premisecitation

    Guanfacine enhances cognition and attention in patients with impairments due to encephalitis or strokes, as long as PFC remains sufficiently intact.

    “Guanfacine has also been shown to enhance cognition and attention in patients with impairments due to encephalitis (Singh-Curry et al., 2011), or strokes, as long as the PFC itself remains sufficiently intact to provide a therapeutic target for drug actions (Malhotra, Parton, Greenwood, & Husain, 2006).”
    Quote in the paperSubstantial claim0 of 2 sources checked
    • cites Singh-Curry et al., 2011

      Couldn’t be matched to a paper in Crossref, so it can’t be checked.

    • cites Malhotra, Parton, Greenwood, & Husain, 2006 source

  • May combine two claims.

    Premisecitation

    Recent studies indicate symptoms of schizotypy have a linear relationship to severe childhood trauma and are associated with worse PFC cognitive functioning.

    “Recent studies indicate that symptoms of schizotypy have a linear relationship to severe childhood trauma, and are associated with worse PFC cognitive functioning (Velikonja et al., 2019).”
    Quote in the paperNot a substantial claim0 of 1 sources checked
    • cites Velikonja et al., 2019 source
    • Rests on an assumption: Patients with schizotypal personality disorder generally do not require antipsychotic medication.

  • Probably not a substantial claim: may not pass S2 (checkable).

    Interpretationreasoning

    A combined approach of boosting PFC physiology while engaged in cognitive training may optimize success.

    “The latter is particularly interesting, as a combined approach of boosting PFC physiology while engaged in cognitive training may optimize success.”
    Quote in the paperNot a substantial claim

  • May combine two claims.

    Premisecitation

    Descent into schizophrenic illness is accompanied by accelerated gray matter loss and signs of inflammation.

    “As the descent into schizophrenic illness is accompanied by accelerated gray matter loss and signs of inflammation (Mongan, Ramesar, Föcking, Cannon, & Cotter, 2019)”
    Quote in the paperSubstantial claim0 of 1 sources checked
    • cites Mongan, Ramesar, Föcking, Cannon, & Cotter, 2019 source

  • May combine two claims.

    Interpretationreasoning

    Guanfacine strengthens connectivity and enhances firing of newly evolved PFC circuits underlying higher cognitive function.

    “In summary, guanfacine strengthens connectivity and enhances the firing of the newly evolved PFC circuits that underlie higher cognitive function.”
    Quote in the paperNot a substantial claim

  • Probably not a substantial claim: may not pass S4 (based).

    Interpretationreasoning

    Some substrate for guanfacine's beneficial actions must remain, i.e. the presence of α2A-AR-expressing PFC dendritic spines.

    “However, some substrate for guanfacine’s beneficial actions must remain, i.e. the presence of α2A-AR -expressing PFC dendritic spines.”
    Quote in the paperNot a substantial claim
42 of 42

  • The paper relies on this without support.

    The mechanisms of guanfacine action in PFC discovered in animals (monkeys, rodents) are the same in humans.

    “one of the rare success stories where basic neuroscience research in animals has successfully translated to human patients”

  • The paper relies on this without support.

    Classic glutamate neurotransmission depends on AMPAR stimulation to depolarize the membrane, eject Mg2+ block from NMDAR pore, and permit NMDAR transmission.

    “Classic glutamate neurotransmission depends on stimulation of AMPAR to depolarize the membrane, to eject the magnesium (Mg2+) block from the NMDAR pore, and permit NMDAR transmission.”

  • The paper relies on this without support.

    The cognitive impairments in the mental disorders discussed are caused by impaired PFC network connectivity of the type guanfacine strengthens.

    “PFC functions are impaired in a host of mental disorders (summarized in Fig. 1B).”

  • The paper relies on this without support.

    Clonidine is more potent than guanfacine in reducing NE release.

    “as clonidine is more potent than guanfacine in this regard.”

  • The paper relies on this without support.

    Rodents do not have a dlPFC or frontal pole.

    “rodents do not have a dlPFC or frontal pole”

  • The paper relies on this without support.

    Many disorders helped by guanfacine have psychological or physiological stress as an etiological factor.

    “many of the disorders that are helped by guanfacine treatment have psychological or physiological stress as an etiological factor.”

  • The paper relies on this without support.

    Oppositional defiant/conduct disorders are often found in children and adolescents who have suffered abuse.

    “These disorders of inappropriate aggression are often found in children and adolescents who have suffered abuse.”

  • The paper relies on this without support.

    Many atypical antipsychotics have α2A-AR-blocking properties.

    “many atypical antipsychotics have complex pharmacological profiles including α2A-AR-blocking properties.”

  • The paper relies on this without support.

    Patients with schizotypal personality disorder generally do not require antipsychotic medication.

    “they generally do not require antipsychotic medication”

  • The paper relies on this without support.

    Ventral PFC regions are important centers for regulation of emotion.

    “consistent with these areas being important centers for the regulation of emotion”
10 of 10

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

  • Guanfacine infusion claim cites a study of an α1 agonist with the opposite effect

    Minor

    The text says Mao et al. (1999) supports improved working memory after guanfacine infusion. The cited reference instead describes an α1 adrenergic agonist infusion that impaired working memory.

  • Two distinct references have the same volume and page range

    Minor

    References 65 and 146 give different articles and journals but assign both volume 106, issue 42, pages 17957-17962 in 2009. Those bibliographic details cannot identify both articles as printed.

2 of 2

Cited works that were retracted

Works this paper cites that were later retracted, from the retraction notices publishers deposit. Major when the notice came out before this paper was published.

  • Cites a retracted work: 10.3389/fphar.2020.00678

    Info

    The cited work was retracted on 2024-08-26 (notice 10.3389/fphar.2024.1483859), not before this paper was published (2020-12).

    Cited work 10.3389/fphar.2020.00678 · retracted 2024-08-26 · notice 10.3389/fphar.2024.1483859 · this paper published 2020-12

1 of 1

Cites

1 retracted

Flagged first, then by citations

Cited by

Sorted by citations

Related

Authors
Arnsten, A. F. T.
Affiliations
Yale University (US)
Corresponding author
Arnsten, Amy F.T.
ORCID
Arnsten, Amy F.T.
Venue
Neurobiology of Learning and Memory
Publisher
Elsevier BV
Published
2020-12
Volume
176
Pages
107327
ISSN
1074-7427 (ISSN-L)
DOI
10.1016/j.nlm.2020.107327
PMC
PMC7567669
OpenAlex
W3092711429
Semantic Scholar
ba90976045a162ed4d83ed411493683c05cf116a
Cited by
75
References
179
Citations by year
2026: 18 · 2025: 16 · 2024: 17 · 2023: 11 · 2022: 9 · 2021: 4
FWCI
2.76
Type
journal article
Language
en
Open access
Licence
Locations
  • Neurobiology of Learning and Memory (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
  • Health Sciences › Medicine › Psychiatry and Mental health › Attention Deficit Hyperactivity Disorder
Keywords
guanfacine, prefrontal cortex, attention deficit hyperactivity disorder, translational research, stress-related disorders, substance abuse, traumatic brain injury, schizotypy, dendritic spines, top-down control, microglia, off-label drug use
MeSH terms
Animals, Attention Deficit Disorder with Hyperactivity, Cognition, Cognition Disorders, Humans, Macaca mulatta, Memory, Short-Term, Nerve Net, Neurons, Synapses, Guanfacine, Prefrontal Cortex, Mice, Rats, Adrenergic alpha-2 Receptor Agonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Claims read by deepseek-v4.1-flash under definition version 3 (extract-v3) on 2026-10-28.

Classified by jev-1.13-20260917 (gold-guideline-v0.2) on 2026-10-28.

Cited sources are checked by gpt-6-sol.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review